Chengdu Easton Biopharmaceuticals Co., Ltd. (SHA:688513)

SHA:688513 Revenue

Chengdu Easton Biopharmaceuticals had revenue of 332.64M CNY in the quarter ending June 30, 2026, a decrease of -4.64%. This brings the company's total for the last twelve months to 1.34B, up 0.09% year-over-year. In the year 2025, Chengdu Easton Biopharmaceuticals had annual revenue of 1.33B, down -1.36%. That makes Chengdu Easton Biopharmaceuticals the 17,479th largest company in the world by revenue and 3,178th in China.

• Revenue (ttm): 1.34B
• Revenue Growth: +0.09%
• P/S Ratio: 5.85
• Revenue / Employee: 943.39K
• Employees: 1,416
• Market Cap: 8.03B

Revenue Chart

Chart

Chart

Revenue by Geography

Chart

• East China 476.68M 35.9%
• Southwest Region 253.79M 19.1%
• Northern China 212.86M 16.0%
• Southern China 164.98M 12.4%
• Central China Region 92.99M 7.0%
• Northeast China Region 58.86M 4.4%
• Northwestern Region 37.56M 2.8%
• Overseas Regions 31.38M 2.4%

Fiscal year ended Dec 31, 2025 See the full SHA:688513 breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	1.33B	-18.37M	-1.36%
Dec 31, 2024	1.35B	232.63M	20.82%
Dec 31, 2023	1.12B	-53.39M	-4.56%
Dec 31, 2022	1.17B	147.58M	14.43%
Dec 31, 2021	1.02B	101.02M	10.96%

Data Source: S&P Global Market Intelligence Last updated: Aug 20, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 21, 2026

Data Sources Report a data error